In a specialist allergy and clinical immunology cohort, representing each patient as a node in a knowledge graph and clustering graph embeddings avoided collapse under random, conditional and value-dependent missingness. The common impute-then-reduce pipeline performed worst under value-dependent missingness, because imputation conflates an untested antibody with a confirmed negative.
Patient stratification no longer has to fill every gap before reducing dimensions. In specialist records, missingness often depends on the missing value itself: autoantibody tests are ordered only when a diagnosis is suspected, and symptoms are recorded mainly when present, so imputation treats an untested antibody and a confirmed negative alike. The usual route imputes medians, then reduces with UMAP, then clusters; under value-dependent missingness that pipeline gave the lowest clustering quality. Across 352 analysable patients in a simulation comparison, the knowledge graph representation had a floor NMI of 0.395 and a range of 0.061 across the three mechanisms, while imputation plus UMAP reached a floor of 0.083 with a range of 0.265.
The construction makes absence carry no information. Each patient is a node, and observed diagnoses, antibody results and symptoms become typed edges to concept nodes; a test with no recorded result adds no edge, so untested is never written as negative. TransE then maps nodes and relations into a vector space, treating each relation as a translation, and k-means clusters the patient vectors. The graph holds 352 patient nodes, 49 concept nodes and 1,408 triples, clustered with k = 6; all seven laboratory biomarkers excluded from graph construction differed significantly across the six clusters after Benjamini-Hochberg correction (q < 0.01).
The findings rest on 359 consecutive patients from a single specialist allergy and clinical immunology unit in Italy, of whom 352 had diagnostic labels and entered the graph experiments. Clustering quality is measured as normalised mutual information against a macro-clinical area label, and the six clusters are externally checked against seven laboratory biomarkers not used to build the graph. The simulation uses discretised laboratory values as a proxy for the missingness structure of antibody and symptom data, covering random, conditional and value-dependent missingness.
The data come from a single specialist centre, and external validity requires multi-centre replication. The primary validation metric shares diagnostic tag information with graph construction, a partial circularity the authors mitigate with independent laboratory biomarker validation. The three simulated mechanisms do not exhaust clinical missingness, TransE and the 64-dimensional embedding were not systematically optimised, and statistical comparisons over five seeds have limited power.